The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
3067 - HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients With Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Phase III Trial